- Home
- SA vs GERN Comparison
SA vs GERN Comparison
Compare SA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SA
- GERN
- Stock Information
- Founded
- SA 1979
- GERN 1990
- Country
- SA Canada
- GERN United States
- Employees
- SA N/A
- GERN N/A
- Industry
- SA Precious Metals
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- SA Basic Materials
- GERN Health Care
- Exchange
- SA Nasdaq
- GERN Nasdaq
- Market Cap
- SA 1.0B
- GERN 878.9M
- IPO Year
- SA N/A
- GERN 1996
- Fundamental
- Price
- SA $12.54
- GERN $1.27
- Analyst Decision
- SA
- GERN Buy
- Analyst Count
- SA 0
- GERN 11
- Target Price
- SA N/A
- GERN $5.80
- AVG Volume (30 Days)
- SA 983.7K
- GERN 15.1M
- Earning Date
- SA 05-12-2025
- GERN 05-07-2025
- Dividend Yield
- SA N/A
- GERN N/A
- EPS Growth
- SA N/A
- GERN N/A
- EPS
- SA N/A
- GERN N/A
- Revenue
- SA N/A
- GERN $76,994,000.00
- Revenue This Year
- SA N/A
- GERN $208.83
- Revenue Next Year
- SA N/A
- GERN $57.49
- P/E Ratio
- SA N/A
- GERN N/A
- Revenue Growth
- SA N/A
- GERN 32386.92
- 52 Week Low
- SA $9.40
- GERN $1.19
- 52 Week High
- SA $20.55
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- SA 59.25
- GERN 34.43
- Support Level
- SA $9.40
- GERN $1.17
- Resistance Level
- SA $13.19
- GERN $1.39
- Average True Range (ATR)
- SA 0.68
- GERN 0.13
- MACD
- SA 0.22
- GERN 0.01
- Stochastic Oscillator
- SA 82.85
- GERN 21.74
About SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.